Combination of acalabrutinib with lenalidomide and rituximab in relapsed/refractory aggressive B-cell non-Hodgkin lymphoma: a single-arm phase II trial
Changhee Park(Seoul National University Hospital), Youngil Koh(Seoul National University)
Cited by 10
Related Papers
Pirtobrutinib in Covalent Bruton Tyrosine Kinase Inhibitor Pretreated Mantle-Cell Lymphoma
|Journal of Clinical Oncology|2023|106
Clinical and Genomic Characteristics of Adult Diffuse Midline Glioma
|Cancer Research and Treatment|2020|49